Hummingbird Bioscience, an innovative biotherapeutics company pioneering the discovery and development of new breakthrough precision antibody therapeutics for difficult-to-treat conditions, today announced that it has raised US$19 million in a Series B financing round.
Hummingbird Bioscience, an innovative systems-biology enabled biotechnology company, has today announced a multi-target collaboration to co-discover novel antibody therapeutics with Amgen. This partnership brings together Hummingbird’s proprietary drug discovery platform with Amgen’s disease expertise and drug development capabilities.
Cancer Research UK, the world’s leading cancer charity, and Hummingbird Bioscience, an innovative systems-biology enabled biotechnology company, have today (Thursday) announced a partnership to develop Hummingbird’s anti-HER3 antibody drug, HMBD-001, for the treatment of people with HER3 driven cancer.
Hummingbird Bioscience, a systems-biology enabled biotech company focused on the discovery and development of novel cancer therapeutics, today announced James P. Allison, Ph.D. and Padmanee Sharma, M.D., Ph.D., have joined its Scientific Advisory Board.